Table 1 |
||||
| Selected average parameters from pressure-volume loop study in vivo assessment of left ventricular function are expressed as mean ± SEM | ||||
| Variables | Control | Dox | Vitamin E Telmisartan | P value |
| End-systolic Volume (uL) | 43.64 ± 1.23 | 69.61 ± 2.36 | 51.34 ± 1.22 | <0.05 |
| End-diastolic Volume (uL) | 69.61 ± 2.37 | 85.03 ± 3.53 | 63.21 ± 1.43 | <0.05 |
| End-systolic Pressure (mmHg) | 70.57 ± 1.22 | 56.64 ± 6.76 | 64.65 ± 1.75 | <0.05 |
| End-diastolic Pressure (mmHg) | 8.36 ± 1.19 | 3.42 ± 0.36 | 7.14 ± 1.54 | <0.05 |
| Ejection Fraction (%) | 42.34 ± 3.21 | 17.35 ± 0.57 | 25.43 ± 1.21 | <0.05 |
| Cardiac Output (ml/min) | 12.67 ± 1.26 | 6.03 ± 0.4 | 7.83 ± 1.17 | <0.51 |
| E MAX | 21.38 ± 2.36 | 14.34 ± 1.32 | 16.43 ± 1. | <0.51 |
P < 0.05, statistically differences between Dox treated only group and with Vitamin E, and Telmisartan treatment; (n = 8 per group).
Hadi et al. BMC Cardiovascular Disorders 2012 12:63 doi:10.1186/1471-2261-12-63
